Catalyst Pharmaceuticals Stock Performance
| CPRX Stock | USD 25.00 0.70 2.88% |
On a scale of 0 to 100, Catalyst Pharmaceuticals holds a performance score of 12. The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Catalyst Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Catalyst Pharmaceuticals is expected to be smaller as well. Please check Catalyst Pharmaceuticals' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Catalyst Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Catalyst Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.88 | Five Day Return 2.52 | Year To Date Return 8.94 | Ten Year Return 1.2 K | All Time Return 313.44 |
1 | Acquisition by Elsbernd Brian of 40000 shares of Catalyst Pharmaceuticals at 22.7 subject to Rule 16b-3 | 11/12/2025 |
2 | Catalyst Pharmaceuticals Recognized as One of North Americas Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 | 11/19/2025 |
3 | Wall Street Analysts Think Catalyst Could Surge 47.37 percent Read This Before Placing a Bet | 12/01/2025 |
4 | Disposition of 1669 shares by Preethi Sundaram of Catalyst Pharmaceuticals subject to Rule 16b-3 | 12/08/2025 |
5 | Disposition of 6746 shares by Harper Molly of Catalyst Pharmaceuticals at 23.06 subject to Rule 16b-3 | 12/12/2025 |
6 | Disposition of 4473 shares by Harper Molly of Catalyst Pharmaceuticals at 23.734 subject to Rule 16b-3 | 12/16/2025 |
7 | Disposition of 38 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3 | 12/29/2025 |
8 | Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- Whats Behind the Move | 12/31/2025 |
9 | Disposition of 2492 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3 | 01/02/2026 |
10 | Disposition of 10577 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3 | 01/05/2026 |
11 | Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of Americas Most Successful Small-Cap Companies | 01/08/2026 |
12 | CPRX or DSNKY Which Is the Better Value Stock Right Now | 01/09/2026 |
13 | Disposition of 71 shares by Kalb Michael Wayne of Catalyst Pharmaceuticals subject to Rule 16b-3 | 01/14/2026 |
14 | Heres Why Catalyst Pharmaceutical is a Strong Value Stock | 01/15/2026 |
15 | How Investors May Respond To Catalyst Pharmaceuticals Rare-Disease Strength And Potential Technical Breakout | 01/16/2026 |
16 | Assessing Catalyst Pharmaceuticals Valuation After Fresh Rare Disease Momentum And Earnings Outperformance | 01/21/2026 |
17 | Disposition of 26334 shares by Patrick McEnany of Catalyst Pharmaceuticals subject to Rule 16b-3 | 01/29/2026 |
18 | AlphaQuest LLC Acquires 30,817 Shares of Catalyst Pharmaceuticals, Inc. CPRX | 02/02/2026 |
| Begin Period Cash Flow | 137.6 M | |
| Total Cashflows From Investing Activities | -556 K |
Catalyst Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,099 in Catalyst Pharmaceuticals on November 6, 2025 and sell it today you would earn a total of 401.00 from holding Catalyst Pharmaceuticals or generate 19.1% return on investment over 90 days. Catalyst Pharmaceuticals is currently generating 0.3101% in daily expected returns and assumes 1.9381% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Catalyst, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catalyst Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Catalyst Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 25.00 | 90 days | 25.00 | roughly 2.5 |
Based on a normal probability distribution, the odds of Catalyst Pharmaceuticals to move above the current price in 90 days from now is roughly 2.5 (This Catalyst Pharmaceuticals probability density function shows the probability of Catalyst Stock to fall within a particular range of prices over 90 days) .
Catalyst Pharmaceuticals Price Density |
| Price |
Predictive Modules for Catalyst Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Catalyst Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Catalyst Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Catalyst Pharmaceuticals is not an exception. The market had few large corrections towards the Catalyst Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Catalyst Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Catalyst Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.23 | |
β | Beta against Dow Jones | 0.28 | |
σ | Overall volatility | 0.98 | |
Ir | Information ratio | 0.11 |
Catalyst Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Catalyst Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Catalyst Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Catalyst Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: AlphaQuest LLC Acquires 30,817 Shares of Catalyst Pharmaceuticals, Inc. CPRX |
Catalyst Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Catalyst Stock often depends not only on the future outlook of the current and potential Catalyst Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Catalyst Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 124.9 M | |
| Cash And Short Term Investments | 517.6 M |
Catalyst Pharmaceuticals Fundamentals Growth
Catalyst Stock prices reflect investors' perceptions of the future prospects and financial health of Catalyst Pharmaceuticals, and Catalyst Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catalyst Stock performance.
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.38 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 2.39 B | ||||
| Shares Outstanding | 122.91 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 3.37 X | ||||
| Price To Sales | 5.36 X | ||||
| Revenue | 491.73 M | ||||
| Gross Profit | 480.67 M | ||||
| EBITDA | 232.9 M | ||||
| Net Income | 163.89 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 3.19 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 7.47 X | ||||
| Cash Flow From Operations | 239.81 M | ||||
| Earnings Per Share | 1.73 X | ||||
| Market Capitalization | 3.1 B | ||||
| Total Asset | 851.41 M | ||||
| Retained Earnings | 285.16 M | ||||
| Working Capital | 502.93 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
About Catalyst Pharmaceuticals Performance
Evaluating Catalyst Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Catalyst Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Catalyst Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 93.24 | 64.69 | |
| Return On Tangible Assets | 0.21 | 0.22 | |
| Return On Capital Employed | 0.24 | 0.25 | |
| Return On Assets | 0.17 | 0.18 | |
| Return On Equity | 0.20 | 0.21 |
Things to note about Catalyst Pharmaceuticals performance evaluation
Checking the ongoing alerts about Catalyst Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catalyst Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Catalyst Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: AlphaQuest LLC Acquires 30,817 Shares of Catalyst Pharmaceuticals, Inc. CPRX |
- Analyzing Catalyst Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catalyst Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Catalyst Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catalyst Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catalyst Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catalyst Pharmaceuticals' stock. These opinions can provide insight into Catalyst Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.